



IFW

ATTORNEY DOCKET NO. 21108.0031U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Ritchlin <i>et al.</i>)	Art Unit: Unassigned
)	
Application No. 10/799,345)	Examiner: Unassigned
)	
Filing Date: March 12, 2004)	Confirmation No. 6683
)	
For: METHODS AND COMPOSITIONS)	
RELATED TO JOINT INFLAMMATION)	
DISEASES)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO 1449 is a listing of documents known to Applicants and/or their attorneys. A copy of each of these documents is enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 21108.0031U2
Application No. 10/799,345

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




David E. Huizenga
Registration No. 49,026

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)


CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Scott Darnell

Date 2-22-05



ATTORNEY DOCKET NO. 21108.0031U2

APPLICATION NO. 10/799,345

SHEET 1 OF 11

**Information Disclosure
Statement List**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A1	Aaronson and Horvath, 2002. A road map for those who don't know JAK-STAT. <i>Science</i> 296:1653-55
	A2	Abu-Amer et al.2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis [In Process Citation]. <i>J Biol Chem</i> 275(35):27307-10.
	A3	Anderson et al.A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. <i>Nature</i> 1997; 390(6656):175-9.
	A4	Anolik et al. 2002. B lymphocyte depletion in the treatment of systemic lupus: phase I/II trial of rituximab in SLE. <i>Arthritis Rheum</i> 47:S289.
	A5	Anolik et al.2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. <i>Arthritis Rheum</i> 48:455-459.
	A6	Antoni, 2003. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis & Rheumatism</i> . 48: (9S):S265
	A7	Arai et al.Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. <i>J Exp Med</i> 1999; 190(12):1741-54
	A8	Arend and Dayer, 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. <i>Arthritis Rheum</i> 33:305-315
	A9	Arend, 2001. The innate immune system in rheumatoid arthritis. <i>Arthritis Rheum</i> 44:2224-34
	A10	Arnett et al.1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. <i>Arthritis Rheum</i> . 31:315-324.
	A11	Azuma et al.2000. Tumor necrosis factor- α induces differentiation of and bone resorption by osteoclasts. <i>J Biol Chem</i> 275:4858-64.
	A12	Baechler et al.2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. <i>Proc Natl Acad Sci U S A</i> 100:2610.
	A13	Bathon et al.2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>N Engl J Med</i> 343(22):1586-93.
	A14	Behar and Porcelli, 1995. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. <i>Arthritis Rheum</i> 38:458-476.

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

A15	Bennett et al.2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. <i>J Exp Med</i> 197:711-723.
A16	Bertolini et al.1986. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. <i>Nature</i> 319:516-518.
A17	Blanco et al. 2001. Induction of dendritic cell differentiation by IFN- α in systemic lupus erythematosus. <i>Science</i> 294:1540-1543.
A18	Boyce et al.Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. <i>J Clin Invest</i> 1992; 90(4):1622-7.
A19	Boyle et al.2003. Osteoclast differentiation and activation. <i>Nature</i> 423:337-342.
A20	Braun et al.2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. <i>Lancet</i> 359:1187-1193.
A21	Bromley and Woolley, 1984. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. <i>Arthritis Rheum.</i> 27:968-975.
A22	Bromley et al.1985. Bidirectional erosion of cartilage in the rheumatoid knee joint. <i>Ann Rheum Dis</i> 44:676.
A23	Bywaters and Dixon, 1965. Paravertebral ossification in psoriatic arthritis. <i>Annals of the Rheum.Dis.</i> 24:313-331.
A24	Campbell et al.2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. <i>J Clin Invest</i> 107(12):1519-1527.
A25	Cenci et al.2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. <i>J Clin Invest</i> 106(10):1229-37.
A26	Chen and Goeddel, 2002. TNF-R1 signaling: a beautiful pathway. <i>Science</i> 296:1634.
A27	Childs et al.. 2001. Efficacy of Etanercept for Wear Debris-Induced Osteolysis. <i>J. Bon. Min. Res.</i> 16:338-47.
A28	Childs et al.2002. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. <i>J Bone Miner Res</i> 17:192-199.
A29	Chomarat et al.2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. <i>Nat Immunol</i> 1:510-514.
A30	Collin-Osdoby et al. 2001. Receptor activator of NF-kB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. <i>J Biol Chem</i> 276(23):20659-72.
A31	Danning et al. 2000. Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. <i>Arthritis Rheum.</i> 43:1244-1256.
A32	Daro et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. <i>J Immunol</i> 2000; 165(1):49-58.
A33	De et al. 2003. Failure of monocytes of trauma patients to convert to immature dendritic cells is related to preferential macrophage-colony-stimulating factor-driven macrophage differentiation. <i>J Immunol</i> 170:6355-6362.
A34	Delneste et al. 2003. Interferon gamma switches monocyte differentiation from dendritic cells to macrophages. <i>Blood</i> 101:143-150.

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

A35	Demulder et al. 1993. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. <i>Endocrinology</i> 133:1978-1982.
A36	den Broeder et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. <i>J Rheumatol</i> 29:2288-2298.
A37	Dougall et al. 1999. RANK is essential for osteoclast and lymph node development. <i>Genes Dev</i> 13(18):2412-24.
A38	Douni et al. 1996. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. <i>J. Inflam.</i> 47:27-38.
A39	Drake et al. 1995. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. <i>J Immunol</i> 154:2441-2447
A40	Esdaile et al. 1981. Deforming arthritis in systemic lupus erythematosus. <i>Ann Rheum Dis</i> 40:124-126.
A41	Faust et al. 1999. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. <i>Journal of Cellular Biochemistry</i> 72:67-80.
A42	Fearon et al. 2003. Angiopoietins, growth factors, and vascular morphology in early arthritis. <i>J Rheumatol</i> 30:260-268.
A43	Feldmann et al. 1996. Rheumatoid arthritis. <i>Cell</i> 85:307-310.
A44	Flick et al. 2003. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. <i>J Orthop Res</i> 21:676-683.
A45	Franzoso et al. 1998. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. <i>J of Exp. Med.</i> 187(2):147-59.
A46	Franzoso et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. <i>Genes & Dev.</i> 11(24):3482-96.
A47	Fujikawa et al. 1996. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. <i>Ann. of Rheum. Dis.</i> 55:816-822.
A48	Gladman et al. 1995. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. <i>J Rheumatol</i> 22:675-679.
A49	Gladman, 1998. Psoriatic arthritis. <i>Rheumatic Diseases Clinics of North America</i> 24:829-844.
A50	Goldenberg and Cohen, 1978. Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. <i>Medicine (Baltimore)</i> 57:239-253.
A51	Goldring and Gravallese, 2000. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. <i>Arthritis Res</i> 2(1):33-7.
A52	Gori et al. 2000. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. <i>Endocrinology</i> 141:4768-4776.
A53	Gravallese et al. 1998. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. <i>Am J Path</i> 152:943-951.
A54	Gravallese et al. 2000. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. <i>Arthritis Rheum.</i> 43:250-258.

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,345
		Filing Date	March 12, 2004
		First Named Inventor	Ritchlin
		Group Art Unit	1616
		Examiner Name	Unassigned

	A55	Gregoretti et al. 1995. Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma. <i>Leukemia</i> 9:1392-1397.
	A56	Grigor et al. 1978. Systemic lupus erythematosus. A prospective analysis. <i>Ann Rheum Dis</i> 37:121-128.
	A57	Hahn, 1998. Antibodies to DNA. <i>N Engl J Med</i> 338:1359-1368.
	A58	Hanekom, et al. 2003. <i>Mycobacterium tuberculosis</i> inhibits maturation of human monocyte-derived dendritic cells in vitro. <i>J Infect Dis</i> 188:257-266.
	A59	Harley et al. 1998. The genetics of human systemic lupus erythematosus. <i>Curr Opin Immunol</i> 10:690-696.
	A60	Helliwell et al. 1991. A re-evaluation of the osteoarticular manifestations of psoriasis. <i>British Journal of Rheumatology</i> 30:339-345.
	A61	Hofbauer and Heufelder, 2000. The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. <i>J Clin Endocrin & Metabolism</i> 85:2355-2363.
	A62	Hofbauer and Heufelder, 2001. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. <i>Arthritis Rheum.</i> 44:253-259.
	A63	Hofbauer et al. 1999. Interleukin-1 β and tumor necrosis factor- α , but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. <i>Bone</i> 25:255-9.
	A64	Hofbauer et al. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. <i>J Bone Miner Res</i> 15:2-12.
	A65	Hsu et al. 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. <i>Proc Natl Acad Sci U S A</i> ; 96(7):3540-5.
	A66	Huang et al. 2000. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. <i>Am J Path</i> 156:761-767.
	A67	Huang et al. 2003. Exposure to receptor-activator of NFkB ligand renders pre-osteoclasts resistant to IFN γ by inducing terminal differentiation. <i>Arthritis Res Ther</i> 5:R49-R59.
	A68	Huang et al. 2003. A Rapid Multiparameter Approach to Study Factors that Regulate Osteoclastogenesis: Demonstration of the Combinatorial Dominant Effects of TNF-alpha and TGF-ss in RANKL-Mediated Osteoclastogenesis. <i>Calcif Tissue Int.</i> 73:584-593
	A69	Iotsova et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2 <i>Medicine</i> 1997; 3(11):1285-9.
	A70	Johnson et al. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. <i>Cell</i> 1992; 71(4):577-86.
	A71	Kaarela and Sarna, 1993. Correlations between clinical facets of outcome in rheumatoid arthritis. <i>Clin Exp Rheumatol</i> 11:643-644.
	A72	Kaarela et al. 1993. How often is seropositive rheumatoid arthritis an erosive disease? A 17-year followup study. <i>J Rheumatol</i> 20:1670-1693.
	A73	Kanematsu et al. . 2000. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. <i>J Bone Miner Res</i> 15:1321-9.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

A74	Kaposi, 1972. New reports on know;edge of systemic lupus erythematosus. <i>Arch Dermat u Syph</i> 4:36.
A75	Karsenty, 1999 The genetic transformation of bone biology. <i>Genes Dev</i> ; 13(23):3037-51.
A76	Keffer et al. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. <i>Embo J</i> 10:4025-31.
A77	Keystone, 2001 Tumor necrosis factor- α blockade in the treatment of rheumatoid arthritis. <i>Rheum Dis Clin North Am</i> ; 27(2):427-43.
A78	Knight et al. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. <i>Mol Immunol</i> 30:1443-1453.
A79	Kobayashi et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. <i>J Exp Med</i> 191:275-86.
A80	Kobayashi et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. <i>Embo J</i> 2001; 20(6):1271-1280.
A81	Kodama et al. 1991. Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. <i>J Exp Med</i> 173:269-72.
A82	Koller et al. 1996 Immunophenotyping of human bone marrow-derived macrophages. <i>Scand J Immunol</i> ; 43(6):626-32.
A83	Kong et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. <i>Neurosurgery</i> 402:304-309.
A84	Kong et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. <i>Nature</i> 397:315-323.
A85	Kono et al. 1994. Lupus susceptibility loci in New Zealand mice. <i>Proc Natl Acad Sci U S A</i> 91:10168-10172.
A86	Kotake et al. 2001. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. <i>Arthritis Rheum.</i> 44:1003-1012.
A87	Kotzin, 1996. Systemic lupus erythematosus. <i>Cell</i> 85:303-306.
A88	Kunisada et al.. 1990. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. <i>Nature</i> 345:442.
A89	Labowitz and Schumacher, Jr., 1971. Articular manifestations of systemic lupus erythematosus. <i>Ann Intern Med</i> 74:911-921.
A90	Lacey et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. <i>Cell</i> 93:165-176.
A91	Lam et al. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. <i>J of Clin. Inv.</i> 106:1481-1488.
A92	Landewé et al. 2003. Serum RANK-ligand Modifies the effect of Disease Activity on Radiographic Progression. <i>Arthritis & Rheumatism</i> 48:S268.
A93	Larsen and Thoen, 1987. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. <i>Scand J Rheumatol</i> 16:395.
A94	Li et al. 2000. NF-kappaB Regulates VCAM-1 Expression on Fibroblast-Like Synoviocytes. <i>J Immunol.</i> 164(11):5990-5997.

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

A95	Li et al. 2002. Systemic TNFa promotes erosive bone resorption by increasing the number of CD11b+ osteoclast progenitors in the periphery which are dependent on RANK signaling for osteoclastogenesis. <i>J Bone & Mineral Res.</i> 17:s130.
A96	Li et al. 2003. The TNF-alpha transgenic mouse model of inflammatory arthritis. <i>Springer Semin Immunopathol</i> 25:19.
A97	Li et al. 2004. Systemic TNFa mediates an increase in peripheral CD11bhi osteoclast precursors in TNFa transgenic mice. <i>Arthritis Rheum</i> 50:265-276
A98	Lipsky et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. <i>N Engl J Med</i> 343:1594-1602.
A99	Locksley et al. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. <i>Cell</i> 104:487-501.
A100	Logan et al. 1996 Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients. <i>Exp Hematol</i> ; 24(1):49-53.
A101	Lomaga et al. 1999 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. <i>Genes Dev</i> ; 13(8):1015-24.
A102	Looney et al. 2002. Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. <i>Arthritis Res</i> 4:59-63.
A103	Maini et al. 1995 Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. <i>Immunol Rev</i> ; 144:195-223.
A104	Maini et al. 1995. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. <i>Immunol Rev</i> 144:195-215.
A105	Martel et al. 1965. The pattern of bone erosion in the hand and wrist in rheumatoid arthritis. <i>Radiology</i> 84:204.
A106	Marzo-Ortega et al. 2001. Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. <i>Arthritis Rheum.</i> 44:2112-2117.
A107	Massey and Flanagan, 1999. Human osteoclasts derive from CD14-positive monocytes. <i>British Journal of Haematology</i> 106:167-170.
A108	McGowan et al. 2001. Cytokine-activated endothelium recruits osteoclast precursors. <i>Endocrinology</i> 142:1678-1681.
A109	McQueen et al. 2003. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. <i>Arthritis Rheum</i> 48:1814-1827.
A110	Mease et al. 1999. Embrel (Etanercept) in patients with Psoriatic Arthritis and Psoriasis. <i>Arthritis Rheum.</i> 42:377 (Abstr.)
A111	Mease et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. <i>Lancet</i> 356:385-390.
A112	Mease, 2002. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. <i>Ann Rheum Dis</i> 61:298-304.
A113	Mills, 1994. Systemic lupus erythematosus. <i>N Engl J Med</i> 330:1871-1879

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
Filing Date	March 12, 2004
First Named Inventor	Ritchlin
Group Art Unit	1616
Examiner Name	Unassigned

A114	Molina et al. 1995. Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. <i>J Rheumatol</i> 22:347-250.
A115	Moll and Wright, 1973. Familial occurrence of psoriatic arthritis. <i>Ann Rheum Dis</i> 32:181-201.
A116	Moll and Wright, 1973. Psoriatic arthritis. <i>Seminars in Arthritis & Rheumatism</i> 3:55-78.
A117	Morel et al. 1994. Polygenic control of susceptibility to murine systemic lupus erythematosus. <i>Immunity</i> 1:219-229.
A118	Moreland et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. <i>N Engl J Med</i> 337:141-147.
A119	Moreland et al. 2001. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. <i>J Rheumatol</i> 28(6):1238-44.
A120	Myers et al. 1999. Expression of functional RANK on mature rat and human osteoclasts. <i>FEBS Letters</i> 463:295-300.
A121	Nakagawa et al. 1998. <i>Biochemical & Biophysical Research Communications</i> 253:395-400.
A122	Nakagawa et al. 1998. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. <i>Biochemical & Biophysical Research Communications</i> 253:395-400.
A123	Natour et al. 1991. A study of synovial membrane of patients with systemic lupus erythematosus (SLE). <i>Clin Exp Rheumatol</i> 9:221-225.
A124	Nicholson et al. 2000. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). <i>Clinical Science</i> 99:133-140.
A125	Partsch et al. 1998. T cell derived cytokines in psoriatic arthritis synovial fluids. <i>Ann. of Rheum. Dis.</i> 57:691-693.
A126	Pascual et al. 2003. The central role of dendritic cells and interferon-alpha in SLE. <i>Curr Opin Rheumatol</i> 15:548-556.
A127	Penit and Vasseur, Phenotype analysis of cycling and postcycling thymocytes: evaluation of detection methods for BrdUrd and surface proteins. <i>Cytometry</i> 1993; 14(7):757-63.
A128	Pettit et al. 2001. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. <i>Am. J. Pathol.</i> 159:1689-1699.
A129	Quinn et al. 1998. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. <i>Endocrinology</i> 139:4424-4427.
A130	Redlich et al. 2002. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. <i>Arthritis Rheum.</i> 46:785-792.
A131	Reece et al. 1999. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. <i>Arthritis Rheum.</i> 42:1481-1484.
A132	Resnick and Niwayama, 1977. On the nature and significance of bony proliferation in "rheumatoid variant" disorders. <i>AJR Am J Roentgen.</i> 129:275-278.
A133	Resnick and Niwayama, 1981. Psoriatic Arthritis. In <i>Diagnosis of Bone and Joint Disorders</i> . D. Resnick and Niwayama, G., editors. W.B. Saunders, Philadelphia. 1103-1129.
A134	Resnick and Niwayama, 1989. Psoriatic Arthritis. In <i>Bone and Joint Imaging</i> . D. Resnick, editor. W. B. Saunders, Philadelphia, PA. 320-328.

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement List (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,345
		Filing Date	March 12, 2004
		First Named Inventor	Ritchlin
		Group Art Unit	1616
		Examiner Name	Unassigned

	A135	Ritchlin and Haas-Smith, 2001. Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells. <i>Journal of Rheumatology</i> 28:698-705.
	A87	Ritchlin and Schwarz, Grant Application, "mechanisms of inflammatory osteolysis in psoriatic arthritis" Howard Hughes Biomedical Research Support Program, July 1, 2001 to June 30, 2002
	A136	Ritchlin et al. 1998. Patterns of Cytokine Production in Psoriatic Synovium. <i>Journal of Rheumatology</i> 25:1544-1552.
	A137	Ritchlin et al. 2003. Etanercept Lowers the Frequency of Circulating Osteoclast Precursors (OCP) and Improves Bone Marrow Edema in Patients with Erosive Psoriatic Arthritis. <i>Late-Breaking Abstract ACR</i> .
	A138	Ritchlin et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>J Clin Invest</i> 2003; 111(6):821-31.
	A86	Ritchlin, Grant Application, Department of Health and Human Services, Public Health Service, "Osteoclastic Bone Resorption in Psoriatic Arthritis" September 1, 2001 to August 31, 2004
	A139	Rozzo et al. 1996. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. <i>Proc Natl Acad Sci U S A</i> 93:15164.
	A140	Rozzo et al. 2000. Enhanced susceptibility to lupus contributed from the nonautoimmune C57BL/10, but not C57BL/6, genome. <i>J Immunol</i> 164:5515-5521.
	A141	Rozzo et al. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. <i>Immunity</i> 15:435-443
	A142	Santiago-Raber et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. <i>J Exp Med</i> 197:777-788.
	A143	Santiago-Schwarz et al. Distinct alterations in lineage committed progenitor cells exist in the peripheral blood of patients with rheumatoid arthritis and primary Sjogren's syndrome. <i>J Rheumatol</i> 1996; 23(3):439-46.
	A144	Schwarz et al. 2000. Anti-TNF α therapy as a clinical intervention for periprosthetic osteolysis. <i>Arthritis Res.</i> 2:165-168.
	A145	Schwarz et al. 1998. NF κ B mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: A mechanism of resistance in p50 knockout mice. <i>J. Virol.</i> 72:5654-5660.
	A146	Schwarz et al. 2003. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. <i>J Orthop Res</i> 21:1049-1055.
	A147	Schwarz, et al. 1997. Immunological defects in mice with a targeted disruption in Bcl-3. <i>Genes Dev</i> 11:187-197.
	A148	Shalhoub et al. 2000. Characterization of osteoclast precursors in human blood. <i>British Journal of Haematology</i> 111:501-512.
	A149	Sharp et al. 1971. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. <i>Arthritis Rheum</i> 14:706-720.
	A150	Sharp et al. 1985. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? <i>Arthritis Rheum</i> 28:1326-1335.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Information Disclosure Statement List (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,345
		Filing Date	March 12, 2004
		First Named Inventor	Ritchlin
		Group Art Unit	1616
		Examiner Name	Unassigned
A151	Shealy et al. 2002. Anti-TNF α antibody allows healing of joint damage in polyarthritic transgenic mice. <i>Arthritis Res</i> 4:R7.		
A152	Shigeyama et al.. 2000. Expression of osteoclast differentiation factor in rheumatoid arthritis. <i>Arthritis Rheum</i> 43:2523-2530.		
A153	Shlomchik et al. 2001. From T to B and back again: positive feedback in systemic autoimmune disease. <i>Nat Rev Immunol</i> 1:147-153.		
A154	Simonet et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. <i>Cell</i> 89:309-319.		
A155	Srivastava et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF- κ B ligand (RANKL)-induced JNK activation. <i>J Biol Chem</i> 2001; 276(12):8836-40.		
A156	Steinman and Nussenzweig, 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. <i>Proc Natl Acad Sci U S A</i> 99:351-358.		
A157	Steinman et al. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. <i>J Exp Med</i> 191:411-416.		
A158	Steinman, 1991. The dendritic cell system and its role in immunogenicity. <i>Annu Rev Immunol</i> 9:271-296.		
A159	Stevens, 1983. The clinical management of systemic lupus erythematosus. In: <i>Shur PH, ed New York: Grune & Stratton</i> :63-83.		
A160	Suda et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. <i>Endocrine Reviews</i> 20:345-357.		
A161	Suda et al. Regulation of osteoclast function. <i>J Bone Miner Res</i> 1997; 12(6):869-79.		
A162	Takahashi et al. 1998. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. <i>J Immunol</i> 161:2629-2635.		
A163	Takayanagi et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN γ . <i>Nature</i> 408:600-605.		
A164	Takayanagi et al. 1997. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. <i>Biochem. Biophys. Res. Comm.</i> 240:279-286.		
A165	Takayanagi et al. 2000. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. <i>Arthritis Rheum</i> 43:259-269.		
A166	Takayanagi et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of <i>interferon</i> β . <i>Nature</i> 416:744-749.		
A167	Tan et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. <i>Arthritis Rheum</i> 25:1271-1277.		
A168	Teitelbaum, 2000. Bone Resorption by Osteoclasts. <i>Science</i> 289:1504-1508.		
A169	Theofilopoulos and Kono, 1999. The genes of systemic autoimmunity. <i>Proc Assoc Am Physicians</i> 111:228-240.		
A170	Thiele et al. 1998. Detection of the bcr/abl gene in bone marrow macrophages in CML and alterations during interferon therapy--a fluorescence in situ hybridization study on trephine biopsies. <i>Journal of Pathology</i> . 186:331-335.		
A171	Toritsuka et al. 1997. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> 24:1690-1696.		

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,345
--------------------	------------

Filing Date	March 12, 2004
-------------	----------------

First Named Inventor	Ritchlin
----------------------	----------

Group Art Unit	1616
----------------	------

Examiner Name	Unassigned
---------------	------------

[illegible]

Examiner Signature: _____

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.